SABCS 2017: Top picks from Dr. William J. Gradishar

 

Oncology Practice Associate Editor William J. Gradishar, MD, reveals several anticipated studies from the 40th annual San Antonio Breast Cancer Symposium, set to begin on Wednesday, Dec. 6:

• GS1-01. Increasing the dose density of adjuvant chemotherapy by shortening intervals between courses or by sequential drug administration significantly reduces both disease recurrence and breast cancer mortality: an EBCTCG meta-analysis of 21,000 women in 16 randomized trials.

• GS4-02. Randomized comparison of adjuvant aromatase inhibitor exemestane plus ovarian function suppression vs. tamoxifen plus OFS in premenopausal women with hormone receptor–positive early breast cancer: Update of the combined TEXT and SOFT trials.

• GS1-03. Perioperative aromatase inhibitor treatment in determining or predicting long-term outcome in early breast cancer–the POETIC Trial.

• GS1-06. Extended adjuvant bisphosphonate treatment over 5 years in early breast cancer does not improve disease-free and overall survival, compared with 2 years of treatment: Phase III data from the SUCCESS A study.

• GS2-05. First-line ribociclib vs. placebo with goserelin and tamoxifen or a nonsteroidal aromatase inhibitor in premenopausal women with hormone receptor–positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial.

• GS2-06. Phase Ib/II study evaluating safety and efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant HER2-positive metastatic breast cancer: Results from the PANACEA (IBCSG 45-13/KEYNOTE-014) study.

• GS2-07. MANTA – A randomized phase 2 study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor–positive advanced or metastatic breast cancer.

• GS3-01. A prospective, randomized, multicenter phase 3 trial of additional 2 versus additional 5 years of anastrozole after initial 5 years of adjuvant endocrine therapy – results from 3,484 postmenopausal women in the ABCSG-16 trial.

• GS3-02. Invasive disease-free survival and gene-expression signatures in CALGB (Alliance) 40601, a randomized phase III neoadjuvant trial of dual HER2 targeting with lapatinib added to chemotherapy plus trastuzumab.

• GS3-03. A phase III, multicenter, double-blind randomized trial of celecoxib versus placebo in primary breast cancer patients (REACT – Randomized European Celecoxib Trial).

• GS3-04. A randomized phase III study of adjuvant trastuzumab for a duration of 9 weeks versus 1 year, combined with adjuvant taxane-anthracycline chemotherapy, for early HER2-positive breast cancer (the SOLD study).

• GS3-06. Long-term follow-up of CALGB 40502/NCCTG N063H (Alliance): A randomized phase III trial of weekly paclitaxel, compared with weekly nanoparticle albumin-bound (nab)–paclitaxel or ixabepilone +/– bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer.

• GS3-08. Pathological complete response predicts event-free and distant disease-free survival in the I-SPY2 TRIAL.

• GS4-01. Pooled analysis of five randomized trials investigating temporary ovarian suppression with gonadotropin-releasing hormone analogues during chemotherapy as a strategy to preserve ovarian function and fertility in premenopausal early breast cancer patients.

• GS4-02. Randomized comparison of adjuvant aromatase inhibitor exemestane plus ovarian function suppression vs. tamoxifen plus OFS in premenopausal women with hormone receptor–positive early breast cancer: Update of the combined TEXT and SOFT trials.

• GS4-03. Randomized comparison of adjuvant tamoxifen plus ovarian function suppression versus tamoxifen in premenopausal women with hormone receptor–positive early breast cancer: Update of the SOFT trial.

• GS4-04. Randomized blinded sham- and waitlist-controlled trial of acupuncture for joint symptoms related to aromatase inhibitors in women with early-stage breast cancer.

• GS5-03. Risk of arm morbidity after local therapy in young breast cancer survivors.

• GS5-05. Primary endocrine therapy for ER-positive ductal carcinoma in situ: CALGB 40903 (Alliance).

• GS6-01. Integration of clinical variables for the prediction of late distant recurrence in patients with estrogen receptor–positive breast cancer treated with 5 years of endocrine therapy.

• GS6-02. The benefit of abemaciclib in prognostic subgroups: An exploratory analysis of combined data from the MONARCH 2 and 3 studies.

• GS6-07. EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician’s choice of therapy in patients with advanced breast cancer and a germline BRCA mutation.
 

Dr. Gradishar is the Betsy Bramsen Professor of Breast Oncology, professor of medicine, and interim chief of the division of hematology/oncology, Northwestern University Feinberg School of Medicine, Chicago, and deputy director for the Clinical Network and director of the Maggie Daley Center for Women’s Cancer Care, Robert H. Lurie Comprehensive Cancer Center Network of Northwestern University, Chicago.

 

Oncology Practice Associate Editor William J. Gradishar, MD, reveals several anticipated studies from the 40th annual San Antonio Breast Cancer Symposium, set to begin on Wednesday, Dec. 6:

• GS1-01. Increasing the dose density of adjuvant chemotherapy by shortening intervals between courses or by sequential drug administration significantly reduces both disease recurrence and breast cancer mortality: an EBCTCG meta-analysis of 21,000 women in 16 randomized trials.

• GS4-02. Randomized comparison of adjuvant aromatase inhibitor exemestane plus ovarian function suppression vs. tamoxifen plus OFS in premenopausal women with hormone receptor–positive early breast cancer: Update of the combined TEXT and SOFT trials.

• GS1-03. Perioperative aromatase inhibitor treatment in determining or predicting long-term outcome in early breast cancer–the POETIC Trial.

• GS1-06. Extended adjuvant bisphosphonate treatment over 5 years in early breast cancer does not improve disease-free and overall survival, compared with 2 years of treatment: Phase III data from the SUCCESS A study.

• GS2-05. First-line ribociclib vs. placebo with goserelin and tamoxifen or a nonsteroidal aromatase inhibitor in premenopausal women with hormone receptor–positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial.

• GS2-06. Phase Ib/II study evaluating safety and efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant HER2-positive metastatic breast cancer: Results from the PANACEA (IBCSG 45-13/KEYNOTE-014) study.

• GS2-07. MANTA – A randomized phase 2 study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor–positive advanced or metastatic breast cancer.

• GS3-01. A prospective, randomized, multicenter phase 3 trial of additional 2 versus additional 5 years of anastrozole after initial 5 years of adjuvant endocrine therapy – results from 3,484 postmenopausal women in the ABCSG-16 trial.

• GS3-02. Invasive disease-free survival and gene-expression signatures in CALGB (Alliance) 40601, a randomized phase III neoadjuvant trial of dual HER2 targeting with lapatinib added to chemotherapy plus trastuzumab.

• GS3-03. A phase III, multicenter, double-blind randomized trial of celecoxib versus placebo in primary breast cancer patients (REACT – Randomized European Celecoxib Trial).

• GS3-04. A randomized phase III study of adjuvant trastuzumab for a duration of 9 weeks versus 1 year, combined with adjuvant taxane-anthracycline chemotherapy, for early HER2-positive breast cancer (the SOLD study).

• GS3-06. Long-term follow-up of CALGB 40502/NCCTG N063H (Alliance): A randomized phase III trial of weekly paclitaxel, compared with weekly nanoparticle albumin-bound (nab)–paclitaxel or ixabepilone +/– bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer.

• GS3-08. Pathological complete response predicts event-free and distant disease-free survival in the I-SPY2 TRIAL.

• GS4-01. Pooled analysis of five randomized trials investigating temporary ovarian suppression with gonadotropin-releasing hormone analogues during chemotherapy as a strategy to preserve ovarian function and fertility in premenopausal early breast cancer patients.

• GS4-02. Randomized comparison of adjuvant aromatase inhibitor exemestane plus ovarian function suppression vs. tamoxifen plus OFS in premenopausal women with hormone receptor–positive early breast cancer: Update of the combined TEXT and SOFT trials.

• GS4-03. Randomized comparison of adjuvant tamoxifen plus ovarian function suppression versus tamoxifen in premenopausal women with hormone receptor–positive early breast cancer: Update of the SOFT trial.

• GS4-04. Randomized blinded sham- and waitlist-controlled trial of acupuncture for joint symptoms related to aromatase inhibitors in women with early-stage breast cancer.

• GS5-03. Risk of arm morbidity after local therapy in young breast cancer survivors.

• GS5-05. Primary endocrine therapy for ER-positive ductal carcinoma in situ: CALGB 40903 (Alliance).

• GS6-01. Integration of clinical variables for the prediction of late distant recurrence in patients with estrogen receptor–positive breast cancer treated with 5 years of endocrine therapy.

• GS6-02. The benefit of abemaciclib in prognostic subgroups: An exploratory analysis of combined data from the MONARCH 2 and 3 studies.

• GS6-07. EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician’s choice of therapy in patients with advanced breast cancer and a germline BRCA mutation.
 

Dr. Gradishar is the Betsy Bramsen Professor of Breast Oncology, professor of medicine, and interim chief of the division of hematology/oncology, Northwestern University Feinberg School of Medicine, Chicago, and deputy director for the Clinical Network and director of the Maggie Daley Center for Women’s Cancer Care, Robert H. Lurie Comprehensive Cancer Center Network of Northwestern University, Chicago.

 

Oncology Practice Associate Editor William J. Gradishar, MD, reveals several anticipated studies from the 40th annual San Antonio Breast Cancer Symposium, set to begin on Wednesday, Dec. 6:

• GS1-01. Increasing the dose density of adjuvant chemotherapy by shortening intervals between courses or by sequential drug administration significantly reduces both disease recurrence and breast cancer mortality: an EBCTCG meta-analysis of 21,000 women in 16 randomized trials.

• GS4-02. Randomized comparison of adjuvant aromatase inhibitor exemestane plus ovarian function suppression vs. tamoxifen plus OFS in premenopausal women with hormone receptor–positive early breast cancer: Update of the combined TEXT and SOFT trials.

• GS1-03. Perioperative aromatase inhibitor treatment in determining or predicting long-term outcome in early breast cancer–the POETIC Trial.

• GS1-06. Extended adjuvant bisphosphonate treatment over 5 years in early breast cancer does not improve disease-free and overall survival, compared with 2 years of treatment: Phase III data from the SUCCESS A study.

• GS2-05. First-line ribociclib vs. placebo with goserelin and tamoxifen or a nonsteroidal aromatase inhibitor in premenopausal women with hormone receptor–positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial.

• GS2-06. Phase Ib/II study evaluating safety and efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant HER2-positive metastatic breast cancer: Results from the PANACEA (IBCSG 45-13/KEYNOTE-014) study.

• GS2-07. MANTA – A randomized phase 2 study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor–positive advanced or metastatic breast cancer.

• GS3-01. A prospective, randomized, multicenter phase 3 trial of additional 2 versus additional 5 years of anastrozole after initial 5 years of adjuvant endocrine therapy – results from 3,484 postmenopausal women in the ABCSG-16 trial.

• GS3-02. Invasive disease-free survival and gene-expression signatures in CALGB (Alliance) 40601, a randomized phase III neoadjuvant trial of dual HER2 targeting with lapatinib added to chemotherapy plus trastuzumab.

• GS3-03. A phase III, multicenter, double-blind randomized trial of celecoxib versus placebo in primary breast cancer patients (REACT – Randomized European Celecoxib Trial).

• GS3-04. A randomized phase III study of adjuvant trastuzumab for a duration of 9 weeks versus 1 year, combined with adjuvant taxane-anthracycline chemotherapy, for early HER2-positive breast cancer (the SOLD study).

• GS3-06. Long-term follow-up of CALGB 40502/NCCTG N063H (Alliance): A randomized phase III trial of weekly paclitaxel, compared with weekly nanoparticle albumin-bound (nab)–paclitaxel or ixabepilone +/– bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer.

• GS3-08. Pathological complete response predicts event-free and distant disease-free survival in the I-SPY2 TRIAL.

• GS4-01. Pooled analysis of five randomized trials investigating temporary ovarian suppression with gonadotropin-releasing hormone analogues during chemotherapy as a strategy to preserve ovarian function and fertility in premenopausal early breast cancer patients.

• GS4-02. Randomized comparison of adjuvant aromatase inhibitor exemestane plus ovarian function suppression vs. tamoxifen plus OFS in premenopausal women with hormone receptor–positive early breast cancer: Update of the combined TEXT and SOFT trials.

• GS4-03. Randomized comparison of adjuvant tamoxifen plus ovarian function suppression versus tamoxifen in premenopausal women with hormone receptor–positive early breast cancer: Update of the SOFT trial.

• GS4-04. Randomized blinded sham- and waitlist-controlled trial of acupuncture for joint symptoms related to aromatase inhibitors in women with early-stage breast cancer.

• GS5-03. Risk of arm morbidity after local therapy in young breast cancer survivors.

• GS5-05. Primary endocrine therapy for ER-positive ductal carcinoma in situ: CALGB 40903 (Alliance).

• GS6-01. Integration of clinical variables for the prediction of late distant recurrence in patients with estrogen receptor–positive breast cancer treated with 5 years of endocrine therapy.

• GS6-02. The benefit of abemaciclib in prognostic subgroups: An exploratory analysis of combined data from the MONARCH 2 and 3 studies.

• GS6-07. EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician’s choice of therapy in patients with advanced breast cancer and a germline BRCA mutation.
 

Dr. Gradishar is the Betsy Bramsen Professor of Breast Oncology, professor of medicine, and interim chief of the division of hematology/oncology, Northwestern University Feinberg School of Medicine, Chicago, and deputy director for the Clinical Network and director of the Maggie Daley Center for Women’s Cancer Care, Robert H. Lurie Comprehensive Cancer Center Network of Northwestern University, Chicago.